Biodelivery Sciences buy klostergang
Summary
This prediction ended on 17.06.21 with a price of €2.94. The prediction had a final performance of 12.39%. klostergang has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Biodelivery Sciences | - | - | - | - |
| iShares Core DAX® | 1.051% | -1.833% | 12.822% | 15.392% |
| iShares Nasdaq 100 | -0.547% | -3.738% | 40.625% | 42.396% |
| iShares Nikkei 225® | -1.778% | -8.115% | 16.092% | 0.891% |
| iShares S&P 500 | 0.002% | -2.226% | 28.387% | 41.095% |
Comments by klostergang for this prediction
In the thread Biodelivery Sciences
BDSI quite attractive at current levels
The overall risk/reward profile of this stock quite attractive at current levels.
Roth Capital reiterated its Buy rating and $4.50 a share price target on BDSI.
Roth's analyst notes,
"We recently met with the management of BioDelivery Sciences. Our key takeaway is that the share price driver over the coming six months is likely to be prescription data for the pain drug Belbuca. Management remains optimistic and the cash runway has recently been strengthened. Maintain Buy rating. Key takeaways from our meetings with BDSI
management include: Business plan update. It appears that the sales operation is already cash flow breakeven."
BDSI has secured two new U.S. patents covering all three of its FDA-approved products: BELBUCA (buprenorphine) buccal film, BUNAVAIL (buprenorphine and naloxone) buccal film and ONSOLIS (fentanyl buccal soluble film). One patent (U.S. Patent Application 15/212912) covers the composition of
the BioErodible MucoAdhesive drug delivery technology for BELBUCA and BUNAVAIL and the other ('288 patent) extends protection on ONSOLIS until July 2027.
Stopped prediction by klostergang for Biodelivery Sciences
Biodelivery Sciences
10.04.17
10.10.17
10.10.17
